Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients
Chen J, Levy A, Tian A, Huang X, Cai G, Fidelle M, Rauber C, Ly P, Pizzato E, Sitterle L, Piccinno G, Liu P, Durand S, Mao M, Zhao L, Iebba V, Felchle H, Mallard de La Varende A, Fischer J, Thomas S, Greten T, Jones J, Monge C, Demaria S, Formenti S, Belluomini L, Dionisi V, Massard C, Blanchard P, Robert C, Quevrin C, Lopes E, Clémenson C, Mondini M, Meziani L, Zhan Y, Zeng C, Cai Q, Morel D, Sun R, Laurent P, Mangoni M, Di Cataldo V, Arilli C, Trommer M, Wegen S, Neppl S, Riechelmann R, Camandaroba M, Neto E, Fournier P, Segata N, Holicek P, Galluzzi L, Buqué A, Alves Costa Silva C, Derosa L, Kroemer G, Chen C, Zitvogel L, Deutsch E. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell 2025, 43: 361-379.e10. PMID: 40068595, PMCID: PMC11907695, DOI: 10.1016/j.ccell.2025.02.010.Peer-Reviewed Original ResearchConceptsPD-L1 blockadeLow-dose irradiationCancer patientsAbscopal effectEfficacy of PD-L1 blockadeCD8<sup>+</sup> T cell activationBenefit of immune checkpoint inhibitorsClinical benefit of immune checkpoint inhibitorsTumor-draining lymph nodesSecond-line immunotherapyImmune checkpoint inhibitorsPhase 2 studyProspective clinical trialTumor-bearing miceCohort of cancer patientsT cell activationMetastatic cancer patientsAnti-cancer efficacyCheckpoint inhibitorsLocal radiotherapyPD-L1Clinical benefitLymph nodesOptimal dosimetryRetrospective cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply